AVP and nephrogenic diabetes insipidus: This suggests that a therapeutic trial with the standard dose of desmopressin is important to differentiate partial CDI, partial nephrogenic diabetes insipidus, and primary polydipsia, if measurements of AVP and copeptin are limited.